Welcome to our dedicated page for Genprex news (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.
Genprex, Inc. develops clinical-stage gene therapies for cancer and diabetes, with recurring updates centered on Reqorsa® Gene Therapy (quaratusugene ozeplasmid) and its diabetes gene therapy candidate Pdx1/MafA, also referred to as GPX-002. Reqorsa uses a non-viral, lipid-based nanoparticle delivery approach for a TUSC2 gene-expressing plasmid and is being developed with approved cancer drugs for non-small cell lung cancer and small cell lung cancer.
Company news commonly covers patent grants and licensed intellectual property for Reqorsa combinations with PD-1 and PD-L1 antibodies, biomarker research involving TROP2 and PTEN, preclinical and clinical data presentations, sponsored research with UT MD Anderson, oncology trial references such as Acclaim-1 and Acclaim-3, diabetes preclinical research, industry conference participation and Nasdaq compliance updates.
Genprex (NASDAQ: GNPX) announced that its executive leadership will attend BIO Europe Spring in Lisbon, Portugal, March 23-25, 2026. Attendees include Ryan Confer, President and CEO, and Thomas Gallagher, SVP of Intellectual Property and Licensing.
Genprex said executives will be available for one-on-one meetings to provide overviews of the company’s gene therapy programs for cancer and diabetes; meeting requests can be made via the conference portal or investors@genprex.com.
Genprex (NASDAQ:GNPX) announced that the Japanese Patent Office issued a favorable appeal decision to grant a patent for REQORSA in combination with PD-L1 antibodies, and the European Patent Office issued a decision to grant a patent for REQORSA with PD-1 antibodies.
Genprex maintains exclusive licenses and says these patents strengthen protection for therapeutic combinations, including the Acclaim-3 small cell lung cancer trial combining REQORSA with PD-L1 antibodies. The company already holds related U.S. and Korea patents, and other international grants and pendings.
Genprex (NASDAQ: GNPX) announced IP Australia issued a Notice of Acceptance on Feb 5, 2026, for a patent application claiming use of Reqorsa® gene therapy combined with PD-L1 antibodies to treat cancers.
The company notes related patents are already granted in the U.S. and Korea and says the patent, if granted, will strengthen exclusivity in Australia while it advances the Acclaim-3 clinical trial and opens an additional site at the University of Kentucky.
Genprex (NASDAQ: GNPX) provided a clinical update for its diabetes gene therapy program for GPX-002 on January 7, 2026, reporting preclinical progress and regulatory planning.
Key developments: preclinical proof-of-concept in Type 2 diabetes mouse and non-human primate models showing beta cell rejuvenation and normalized glucose; prior T1D models showed restored normal glucose and improved c-peptide/insulin metrics; manufacturing process transferred to CDMO partners; and a FDA meeting request submitted by end of 2025, with the meeting scheduled in Q1 2026 to discuss IND-enabling studies and next steps toward toxicology studies and cGMP clinical scale production.
Genprex (NASDAQ: GNPX) announced preliminary preclinical in vivo proof-of-concept data for GPX-002, a diabetes gene therapy, from Type 2 diabetic non-human primate (NHP) and mouse studies dated Jan 6, 2026. Key findings: one NHP treated via pancreatic duct infusion achieved normal glucose tolerance at seven months; a second NHP treated by direct pancreatic injection improved glucose tolerance at three months but did not normalize; T2D mice showed statistically significant glucose tolerance improvement at four weeks and restoration of normal glucose levels. Studies used an AAV vector carrying Pdx1 and MafA with an insulin promoter. Ongoing work includes toxicology and IND planning.
Genprex (NASDAQ: GNPX) reported publication of Acclaim-1 Phase 1 data in Clinical Lung Cancer on Nov 24, 2025, evaluating REQORSA (quaratusugene ozeplasmid) with osimertinib in advanced EGFR-mutant NSCLC after progression on prior osimertinib.
The Phase 1 dose-escalation (12 patients) found no dose-limiting toxicities, set a recommended Phase 2 dose (RP2D) of 0.12 mg/kg, and reported early signs of efficacy including one investigator-assessed partial remission continuing >32 months and two patients with prolonged progression-free survival.
Genprex (NASDAQ: GNPX) announced on November 19, 2025 that it added Gabrail Cancer Center in Canton, Ohio as a new clinical trial site for its Acclaim-1 and Acclaim-3 studies of Reqorsa gene therapy (quaratusugene ozeplasmid) in lung cancer.
The company noted the Acclaim trials are supported by FDA Fast Track designation and said it expects to add additional sites over the coming months to expand patient access and expedite enrollment.
Genprex (NASDAQ: GNPX) announced the USPTO granted a U.S. patent covering use of its lead candidate Reqorsa gene therapy in combination with PD-L1 antibodies (example: Tecentriq) for cancer treatment, with protection through 2037. The patent is said to apply to Genprex's Acclaim-3 clinical trial in small cell lung cancer and is already granted in the U.S. and Korea. Genprex is pursuing additional patent applications in Europe, Canada, Brazil, China, and Israel, which the company says would extend protection to those trials if granted.
Genprex (NASDAQ: GNPX) announced that the European Patent Office has communicated its intent to grant a patent for the use of Reqorsa gene therapy (quaratusugene ozeplasmid) in combination with PD-1 antibodies to treat cancer (Nov 4, 2025).
This expands Genprex's patent estate that already includes granted patents for the same combination in the U.S., Japan, Mexico, Russia, Australia, Chile, China, and Singapore. Reqorsa is being developed alongside approved cancer drugs for lung cancer, with preclinical data showing complementarity with targeted drugs and immunotherapies.
The release cites EU and global lung cancer burden: ~250,000 EU deaths in 2021, 11.9% of new cancer diagnoses in EU-27 (2020), and GLOBOCAN 2022 estimates of ~2.48M new global cases and ~1.8M deaths.
Genprex (NASDAQ: GNPX) announced a registered direct offering of 377,780 shares at $9.00 per share for gross proceeds of about $3.4 million, priced at-the-market under Nasdaq rules. In a concurrent private placement, Genprex will issue unregistered short-term warrants to buy up to 755,560 shares at $8.75 per share, exercisable immediately and expiring 24 months after effectiveness of a resale registration statement, which could generate up to $6.6 million if fully exercised.
The offering is expected to close on or about October 29, 2025, H.C. Wainwright & Co. is placement agent, and net proceeds are intended for working capital and general corporate purposes. No assurance warrants will be exercised.